Results:
At a median follow-up of 48 months (range: 25-112) one (0.9%) local recurrence was observed. Two patients (1.9%) died of internal disease. One (0.9%) contralateral recurrence and three (2.8%) secondary tumours were observed. Neither regional nor distant failure was detected. Acute side effects included grade 1 (G1) and G2 erythema in 54 (51.9%) and 2 (1.9%), G1 parenchymal induration in 43 (41.3%), G1 and G2 pain in 26 (25%) and 2 (1.9%) patients. No ≥G3 or higher acute side effect occurred. Late side effects included G1 telangiectasia in 10 (9.6%) G1, G2, and G3 fibrosis in 26 (25%), 3 (2.8%) and 1 (0.9%) patients respectively. Asymptomatic (G1) fat necrosis occurred in 8 (7.7%) patients. The rate of excellent/good and fair/poor cosmetic results was 96 (92.3%), 8 (7.7%) respectively.
Conclusion:
Both 3D-CRT and IG-IMRT for delivery the ABPI is feasible and the 4 years clinical results and toxicity profile is comparable to other results using multicatheter APBI brachytherapy. Purpose or Objective: Radiation and anthracyclines are known to induce cardiac damage. Despite the use of 3D planning the heart is still irradiated with non-negligible doses, therefore this problem needs further investigation. We perform an analysis of cardiac function in the left sided breast cancer survivors. Patients were treated with surgery alone (S), additional radiation (RT), additional anthracycline based chemotherapy (A) or both (RA).
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Material and Methods:
A total of 140 patients were subjected to cardiological evaluation more than 8 years after primary treatment. We performed ECG and ECHO (in a part of patients we also had an ECG and ECHO performed before surgery), blood tests, chest X-ray. We also collected additional relevant information on patients (history, comorbidities, current treatment, etc.) . Distribution of patients was as follows 50% RA arm, 18% S, 8% RT, 24% A. The mean time from the beginning of the treatment to examination was 12.2 years (8-15.9) in S, 11.7 (8-16.9) in A, 10.7 (8-15.3) in RT, 10.1 (8.1-14.5) in RA. The majority of patients were treated with amputation (74%), the remaining with BCT. In chemotherapy arms 47% were treated with FAC, 31% with CAF, 19% with AC, and 3% with TE. Hormonal treatment was given to 64% of patients, in the majority of them it was Tamoxifen-based. Radiotherapy dose varied between 50 and 70 Gy.
Results:
There was no significant difference in ejection fraction (EF) between the groups: median 56 (47-65) in S, 50 (25-65) in A, 55 (47-62) in in RA. Other evaluated parameters like size of the right and left ventricle, left atrium, thickness of septum and posterior wall also did not differ between groups. In the whole group in 21% of patients we observed chronic cardiac insufficiency. In 58% of patients there were other cardiovascular disorders as hypertension, hypercholesterolemia, atherosclerosis, arrhythmias, and valvular disorders. Only in one patient treated with radiation and chemotherapy we found impaired heart function without other additional causes.
Conclusion:
In the current series no unequivocal association between treatment regimen and long-term cardiac dysfunction could be found. Further studies in a wellbalanced patient population are needed to elucidate the impact of contemporary anthracycline-based systemic treatment and modern irradiation techniques on cardiac outcome. Purpose or Objective: Incidental radiation dose to the heart and lung during left breast radiation therapy (RT) has been associated with an increased risk of cardiopulmonary morbidity especially in patients treated with antracyclin as neoadjuvant/adjuvant chemotherapy schedules after surgery. We conducted two different dosimetric analyses (by NTCP and Bio-DVH) to determine if left breast RT with the Active Breathing Coordinator (ABC) can reduce heart/left anterior descending artery (LAD) and lung dose without target coverage impairment.
Material and Methods:
Patients with stages 0-III left breast cancer (LBC) were enrolled and underwent simulation with both free breathing (FB) and ABC for comparison of dosimetry. ABC was used during the patient's RT course if the heart exposition was V(30) ≥ 12%. The prescription dose was 50 Gy plus a boost in 88% and 2,75 Gy up to 44 Gy plus a boost in 22%. The primary endpoint was the magnitude of S568 ESTRO 35 2016 _____________________________________________________________________________________________________ heart reduction dose when comparing ABC to FB. Analysis was performed with BIOPLAN (BiOlogical evaluation of PLANs) PC based user-friendly software (evaluation of Dmax, Dmin, Dmean) and home-made Planning Reporting Orienteering (PRO)-DVH software. PRODVH produced Bio-DVH (Equivalent Dose Volume histograms for 25 fractions) that allowed the comparison regardless of the treatment schedule and that were used to calculate the average DVH for each set up. Secondary endpoints included dose reduction to the lung and procedural success rate.
Results:
Between May 2012 to February 2015, 50 patients with LBC are selected for receiving RT using ABC after both FB and ABC simulation. Procedural success was good, all patients have sufficient compliance and are been selected for this procedure. The primary endpoint was achieved: use of ABC reduced LAD/heart exposition (p < 0.01 T-student test). There was no significant difference between the freebreathing and moderate deep inspiration breath-holding in the target volume coverage. The volume of the ipsilateral lung in the free-breathing technique was smaller than the moderate deep inspiration breath-holding techniques. All these data were confirmed with both software.
Conclusion: ABC was well tolerated and significantly reduced heart/LAD dose without impairment in target volume coverage. No difference was find in lung dose reduction. Use of the ABC device during RT should be considered to reduce the risk of ischemic heart disease in populations at risk.
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Atlas-based segmentation for delineating the locoregional node levels during breast radiotherapy C. Pirson Purpose or Objective: Proper multi-atlas automated delineation can streamline clinical routine only when the proposed volume determination reasonably approximates the manual delineation. In this investigation we aimed to evaluate the automatic atlas-based segmentation of supraclavicular and level 3 lymph nodes for loco-regional irradiation of breast cancer. Further analysis were performed on the final plan's dose coverage to the automated clinical target volume.
Material and Methods:
Between June and September 2015 five consecutive breast cancer patients with clinical indication for loco-regional irradiation were selected. Predefined breast delineation atlas of Mirada RTx (version 1.6.2, Mirada Medical, Oxford, United Kingdom) software were used to generate automated clinical target volumes (CTVauto) including the supraclavicular and the axillary level 3 lymph nodes. Responsible radiation oncologist delineated the reference CTV (CTVref) for each individual patients as well. Comparison metrics of Dice similarity (DI) and commonly contoured volume (CCV) were used. Furthermore the CTVauto was expanded with 1,2,3,4 and 5 mm uniform margin consecutively followed by an evaluation of the volumetric coverage of CTVref. Finally clinical plans were created expanding CTVref with 5 mm uniform margin using either direct antero-posterior beam or multi-beam IMRT. Dose coverage of the 95% of prescribed dose (V95) were compared for both CTVs.
Results:
The average CTVref was 35.1 cc (Standard deviation = 10.2), while for the CTVauto 42.1 cc (SD = 12.1). Mean DI and CCV were 0.73 (SD: 0.26) and 0.72 (SD: 0.28) respectively. Expanding the CTVauto up to 5 mm in 1 mm increments covered the CTVref with 53.9%, 77.9%, 88.1%, 90.9% , 92.7% and 95.7% respectively. (Figure 1 ). For two patients single direct ante-posterior (AP) beam were used for the loco-regional treatment, while for the other three cases 6 beam IMRT were used. Average V95% dose coverage of CTVref was 98.5% (SD: 3.0) which lowered to 92.0% (SD: 9.1%) for CTVauto. For the two patient with single AP field the CTVref were 93.0% and 99.5%, which dropped to 79.8% and 99.4% for CTVauto. The multi-beam IMRT cases showed 100%, 99.9% and 99.8% CTVref_V95 and 100%, 88.5% and 94.0% CTVauto_V95.
Conclusion: CTV delineation using an atlas-based autosegmentation shows promising results even in a small complicated volume delineation such as the loco-regional lymph nodes of breast. Further improvement of the delineation accuracy is expected by adding more cases to the initial multi-atlas (with 3 provided cases).
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Hypofractionated radiotherapy in locally advanced breast cancer A.C. Carvalho 
